1. Disclaimer
We do not guarantee the accuracy, currency or completeness of information regarding medications or medical products, and official sources should be verified before making any decisions. By using this blog, you agree to assume personal responsibility for relying on the information provided.
This commentary is intended for educational and informational purposes and does not replace the current approved product information, prescribing information, package leaflet, or advice from a qualified healthcare professional. Product formulations, approved indications, strengths, routes of administration, contraindications, and availability may differ between countries and may change over time. The current Egyptian package leaflet and the instructions supplied with the specific MOBITIL presentation should therefore be checked before prescribing or dispensing.
2. Summary
MOBITIL® is an Egyptian brand of meloxicam, a nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class. It provides analgesic and anti-inflammatory effects primarily through inhibition of cyclooxygenase (COX) enzymes and subsequent reduction of prostaglandin synthesis.
Current Egyptian-market information identifies MOBITIL presentations including:
- MOBITIL 7.5 mg tablets — 10 tablets
- MOBITIL 15 mg tablets — 6 tablets
- MOBITIL 15 mg/1.5 mL ampoules — 3 ampoules
- MOBITIL 15 mg suppositories — 6 suppositories
Medical Union Pharmaceuticals (MUP) is identified as the manufacturer of MOBITIL, and current product databases list the brand as available in tablet, ampoule, and suppository forms.
Meloxicam is principally used for symptomatic treatment of inflammatory and degenerative musculoskeletal disorders, particularly osteoarthritis and rheumatoid arthritis. Depending on the formulation and jurisdiction, other uses may be approved or described in product information.
Like other systemic NSAIDs, meloxicam carries important gastrointestinal, cardiovascular, renal, hepatic, hypersensitivity, and pregnancy-related risks. Modern safety information emphasizes that these risks are not eliminated simply because meloxicam preferentially inhibits COX-2.
3. Brand Name
MOBITIL®
The brand is marketed in Egypt by Medical Union Pharmaceuticals (MUP).
Current Egyptian-market sources identify MOBITIL as a meloxicam product available in tablets, ampoules, and suppositories.
4. Category
Pharmacological class:
- Nonsteroidal anti-inflammatory drug (NSAID)
- Oxicam derivative
- Enolic-acid NSAID
ATC classification:
- M01AC06 — Meloxicam
Meloxicam is an NSAID with preferential, but not absolutely selective, inhibition of COX-2 at therapeutic concentrations.
5. Active Ingredient
Meloxicam
Chemical name:
4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide
Molecular formula:
C14H13N3O4S2
Molecular weight:
351.4 g/mol
Meloxicam is a member of the oxicam family of NSAIDs.
6. Pharmaceutical Form & Strength
Current Egyptian-market information identifies the following MOBITIL presentations:
| Presentation | Strength | Pack |
|---|---|---|
| MOBITIL tablets | 7.5 mg | 10 tablets |
| MOBITIL tablets | 15 mg | 6 tablets |
| MOBITIL injection | 15 mg/1.5 mL | 3 ampoules |
| MOBITIL suppositories | 15 mg | 6 suppositories |
MUP product listings identify MOBITIL as being available as tablets, ampoules, and suppositories, including 7.5 mg tablets, 15 mg tablets, 15 mg suppositories, and 15 mg ampoules.
Important: availability and regulatory status of a particular strength or route should always be confirmed against the currently marketed Egyptian package and official local registration information.
7. Manufacturer & Marketing Authorization Holder
Manufacturer:
Medical Union Pharmaceuticals (MUP), Egypt
The historical product information supplied with this commentary identifies the manufacturer as:
Medical Union Pharmaceuticals
Abu-Sultan, Ismailia, Egypt
External product information also identifies Medical Union Pharmaceuticals as the manufacturer of MOBITIL.
Marketing Authorization Holder (MAH):
The available publicly accessible sources reviewed for this update do not provide sufficiently reliable current documentation to independently establish a separate MAH distinct from MUP for every current MOBITIL presentation.
Therefore, it is preferable not to state a separate MAH as fact unless it is confirmed from the current Egyptian regulatory registration or the current approved MOBITIL leaflet.
8. Mechanism of Action
Meloxicam inhibits the cyclooxygenase pathway responsible for conversion of arachidonic acid into prostaglandin precursors.
It reduces prostaglandin synthesis, resulting in:
- Reduced inflammation
- Reduced peripheral pain sensitization
- Reduced inflammatory pain
- Reduction of fever to some extent
Meloxicam has preferential inhibition of COX-2 over COX-1, particularly at therapeutic concentrations.
COX-1
COX-1 is constitutively expressed in many tissues and contributes to:
- Gastric mucosal protection
- Platelet thromboxane production
- Renal physiological prostaglandin production
COX-2
COX-2 is induced in many inflammatory states and contributes substantially to:
- Inflammatory prostaglandin production
- Pain
- Tissue inflammation
The preferential COX-2 activity of meloxicam may contribute to its gastrointestinal tolerability profile compared with some less COX-2-preferential NSAIDs; however, meloxicam is not a coxib and does not eliminate gastrointestinal or cardiovascular NSAID risks.
The modern clinical warning for meloxicam continues to emphasize potentially serious cardiovascular thrombotic events and gastrointestinal bleeding, ulceration, and perforation.
9. Spectrum of Activity
Not applicable in the antimicrobial sense.
Meloxicam is not an antibiotic or antimicrobial agent and therefore has no antibacterial, antiviral, antifungal, or antiparasitic spectrum.
Its pharmacological activity is instead:
- Analgesic
- Anti-inflammatory
- Antipyretic
Its therapeutic effect results from inhibition of prostaglandin synthesis rather than antimicrobial activity.
10. Pharmacokinetics
Absorption
After oral administration, meloxicam is well absorbed, with high systemic bioavailability.
Food does not substantially alter the overall extent of absorption, although taking oral meloxicam with food may improve gastrointestinal tolerability.
The supplied historical MOBITIL information states that absorption following intramuscular administration is complete.
Distribution
Meloxicam is highly protein bound:
- Approximately 99% bound to plasma proteins, predominantly albumin.
This high protein binding is clinically relevant when considering interactions with other highly protein-bound medicines, although displacement alone does not necessarily produce a clinically significant interaction.
PubChem reports approximately 99.4% protein binding.
Steady State
Because meloxicam has a relatively long elimination half-life, repeated once-daily administration results in accumulation.
Steady-state concentrations are generally reached after approximately 3–5 days of repeated administration.
The historical MOBITIL information supplied with this review states that steady-state plasma concentrations are achieved within approximately 3–5 days with 15 mg once-daily dosing.
Metabolism
Meloxicam undergoes extensive hepatic metabolism.
The principal metabolic pathway involves CYP2C9, with a smaller contribution from CYP3A4.
Several metabolites are formed and are considered pharmacologically inactive.
The major metabolic transformation includes oxidation of the methyl group of the thiazolyl moiety.
PubChem identifies CYP2C9 as the major enzyme involved, with a minor contribution from CYP3A4.
Elimination
Meloxicam metabolites are eliminated through both:
- Urine
- Feces
Only a very small proportion of the administered dose is eliminated as unchanged meloxicam.
The historical MOBITIL leaflet states that elimination of a single dose is essentially complete within approximately five days.
Elimination Half-Life
The terminal elimination half-life is approximately:
15–20 hours
The historical MOBITIL information gives approximately:
17–20 hours
This relatively long half-life supports once-daily administration.
PubChem reports a half-life of approximately 15–20 hours.
Clearance
The historical MOBITIL information reports total plasma clearance of approximately:
0.42–0.48 L/hour
It also states that pharmacokinetic parameters are approximately linear over the 7.5–30 mg dose range.
These numerical values should be interpreted as historical pharmacokinetic data rather than as a substitute for the current approved product information.
Renal Impairment
Meloxicam should be used cautiously in patients with renal impairment because NSAIDs can reduce renal prostaglandin synthesis and thereby impair renal perfusion.
Patients at increased risk include those with:
- Chronic kidney disease
- Dehydration or hypovolemia
- Heart failure
- Older age
- Concurrent diuretic therapy
- Concurrent ACE inhibitor or ARB therapy
The historical MOBITIL information states that patients with terminal renal failure may have an increased volume of distribution and that the daily dose should not exceed 7.5 mg in dialysis patients.
However, dosing recommendations should be based on the current approved local product information, particularly because NSAID use in severe renal impairment may be inappropriate rather than simply a matter of dose reduction.
Hepatic Impairment
Meloxicam is extensively metabolized in the liver.
Mild-to-moderate hepatic impairment may not substantially alter pharmacokinetics, but patients with significant hepatic disease may have increased susceptibility to NSAID-related adverse effects.
Severe hepatic impairment is generally a contraindication or strong reason to avoid systemic meloxicam depending on the applicable product label.
11. Indications
The principal established indications for meloxicam include symptomatic treatment of:
Osteoarthritis
For relief of:
- Pain
- Tenderness
- Stiffness
- Inflammatory symptoms associated with osteoarthritis
Rheumatoid Arthritis
For symptomatic relief of:
- Joint pain
- Swelling
- Stiffness
- Inflammation
Ankylosing Spondylitis
Meloxicam may be used for symptomatic management of inflammatory spinal pain and stiffness where approved.
MedlinePlus identifies osteoarthritis and rheumatoid arthritis as established indications and also describes use in ankylosing spondylitis.
Juvenile Idiopathic Arthritis
Meloxicam has pediatric indications in some formulations/jurisdictions for juvenile idiopathic arthritis in children 2 years and older, but this does not automatically mean that every MOBITIL formulation is approved for pediatric use.
The specific Egyptian product leaflet should therefore be checked before pediatric prescribing.
Additional Indications Listed in the Historical MOBITIL Information
The older MOBITIL information supplied for this review also lists:
- Symptomatic treatment of acute exacerbations of inflammatory and degenerative rheumatic diseases
- Rheumatoid arthritis
- Osteoarthritis
- Ankylosing spondylitis
- Post-traumatic pain, inflammation, and swelling
- Post-operative pain, inflammation, and swelling
- Painful syndromes of the vertebral column
- Painful and/or inflammatory gynecological conditions such as primary dysmenorrhea or adnexitis
- Painful and/or inflammatory dental conditions
These indications were included in the historical product information provided by the user.
However, they should not automatically be assumed to remain current approved indications for every present-day MOBITIL formulation. Current product-specific approval should be confirmed from the current Egyptian package leaflet/registration documentation.
12. Administration
Oral Tablets
Meloxicam tablets are generally administered:
Once daily
The total daily dose should normally be administered as a single daily dose.
The usual adult dose is:
7.5 mg once daily
If necessary and clinically appropriate:
15 mg once daily
The maximum recommended systemic daily dose is generally:
15 mg/day
The lowest effective dose for the shortest duration necessary should be used.
Oral meloxicam can generally be taken with or without food, although taking it with food may improve gastrointestinal tolerability.
Rectal Suppositories
The currently identified MOBITIL suppository contains:
15 mg meloxicam per suppository
Historical/current Egyptian pharmacy information describes administration as:
One 15 mg suppository once daily by the rectal route.
The total daily meloxicam dose should not exceed 15 mg/day.
The suppository should be administered rectally and should not be swallowed.
The current local package leaflet should be followed regarding the exact approved indications and duration.
Intramuscular Injection
The supplied historical MOBITIL presentation contains:
15 mg meloxicam in 1.5 mL
The historical product information specifies:
15 mg once daily by deep intramuscular injection
and recommends administration into the upper outer quadrant of the buttock, alternating sides if repeated injections are required.
It also states that in patients with a hip prosthesis, injection should be administered on the opposite side.
Important update
The historical leaflet describes a deep intramuscular route for the MOBITIL ampoule. This route should not be generalized to every meloxicam injection product worldwide because different meloxicam injectable formulations have different approved routes and indications.
For MOBITIL specifically, the current ampoule package insert should be followed.
13. Method of Preparation
Tablets
No preparation or reconstitution is required.
Swallow with an adequate amount of water.
Suppositories
No reconstitution is required.
The suppository is ready for rectal administration.
Ampoules
The historical MOBITIL ampoule is described as a ready-to-use 1.5 mL solution containing 15 mg meloxicam.
No dilution or reconstitution is described in the supplied historical product information.
It should therefore not be mixed with other injectable medicines or diluted unless this is specifically authorized by the current manufacturer instructions or compatibility data.
Administration should be performed by an appropriately trained healthcare professional.
14. Contraindications
Important contraindications/avoidance situations include:
- Hypersensitivity to meloxicam
- Hypersensitivity to other oxicam NSAIDs
- Previous NSAID-induced asthma, urticaria, angioedema, or other serious hypersensitivity reactions
- History of serious NSAID-related gastrointestinal bleeding or perforation
- Active peptic ulcer disease
- Severe gastrointestinal bleeding
- Severe hepatic impairment
- Severe renal impairment, particularly when not receiving dialysis
- Severe heart failure, where specified by the applicable product information
- Significant bleeding disorders
- Certain cerebrovascular bleeding conditions
- Pregnancy at contraindicated gestational stages according to the applicable regulatory labeling
The historical MOBITIL leaflet specifically lists hypersensitivity to oxicams, active peptic ulcer, severe hepatic insufficiency, and severe non-dialyzed renal insufficiency.
Modern NSAID labeling also emphasizes serious cardiovascular and gastrointestinal risks.
15. Warnings & Precautions
15.1 Cardiovascular Risk
Systemic NSAIDs, including meloxicam, may increase the risk of serious cardiovascular thrombotic events such as:
- Myocardial infarction
- Stroke
These events can be fatal.
The risk may occur relatively early in treatment and may increase with duration of use.
Patients with:
- Established cardiovascular disease
- Hypertension
- Diabetes
- Hyperlipidemia
- Smoking history
- Previous myocardial infarction
- Previous stroke
require particular caution.
Current meloxicam labeling carries a prominent warning concerning serious cardiovascular and gastrointestinal events.
15.2 Gastrointestinal Toxicity
Meloxicam can cause:
- Dyspepsia
- Gastritis
- Peptic ulceration
- Gastrointestinal bleeding
- Gastrointestinal perforation
Serious gastrointestinal events may occur without warning symptoms.
Risk is increased by:
- Older age
- Previous peptic ulcer disease
- Previous gastrointestinal bleeding
- High NSAID doses
- Long treatment duration
- Concomitant corticosteroids
- Anticoagulants
- Antiplatelet agents
- SSRIs/SNRIs
- Alcohol consumption
Patients at high gastrointestinal risk may require gastroprotective therapy where clinically appropriate.
15.3 Renal Toxicity
NSAIDs can reduce renal prostaglandin synthesis and cause:
- Acute kidney injury
- Sodium and water retention
- Edema
- Hyperkalemia
- Worsening hypertension
- Worsening heart failure
Risk is particularly important in patients with pre-existing renal disease, dehydration, heart failure, or concurrent renin–angiotensin system blockade and diuretic therapy.
15.4 Hepatic Effects
Abnormal liver function tests may occur.
Rarely, clinically significant hepatic injury may develop.
Patients with existing liver disease should be monitored appropriately.
15.5 Hypersensitivity
Serious hypersensitivity reactions, including:
- Anaphylaxis
- Angioedema
- Bronchospasm
- Severe cutaneous reactions
may occur.
Patients who have developed asthma, nasal polyps, urticaria, or angioedema after aspirin or another NSAID may have cross-reactive NSAID hypersensitivity.
15.6 Severe Cutaneous Adverse Reactions
Rare but potentially life-threatening reactions such as:
- Stevens–Johnson syndrome (SJS)
- Toxic epidermal necrolysis (TEN)
- Drug reaction with eosinophilia and systemic symptoms (DRESS)
have been associated with NSAIDs.
Meloxicam should be discontinued at the first appearance of a progressive skin eruption, mucosal lesions, blistering, or other signs suggestive of a severe cutaneous adverse reaction.
15.7 Fluid Retention and Edema
Meloxicam may cause:
- Peripheral edema
- Sodium retention
- Fluid retention
Caution is required in:
- Heart failure
- Hypertension
- Renal impairment
15.8 Blood Pressure
NSAIDs may cause new or worsening hypertension and may reduce the antihypertensive effects of some medications.
Blood pressure should be monitored in patients receiving prolonged therapy.
15.9 Masking of Infection
NSAIDs may reduce fever and inflammatory symptoms and therefore potentially mask clinical manifestations of infection.
They should not be used as a substitute for appropriate diagnosis and treatment of an underlying infection.
16. Drug Interactions
Anticoagulants
Examples:
- Warfarin
- Direct oral anticoagulants
Combination may substantially increase bleeding risk.
Antiplatelet Drugs
Examples:
- Aspirin
- Clopidogrel
Concomitant use may increase gastrointestinal bleeding risk.
Other NSAIDs
Examples:
- Ibuprofen
- Diclofenac
- Naproxen
- Ketorolac
- Indomethacin
- Piroxicam
- Celecoxib and other COX-2 inhibitors
Combining NSAIDs generally increases toxicity without providing a clinically useful additive benefit.
Do not routinely combine meloxicam with another systemic NSAID.
Corticosteroids
Examples:
- Prednisolone
- Dexamethasone
- Methylprednisolone
Combination may increase gastrointestinal ulceration and bleeding risk.
SSRIs/SNRIs
Examples:
- Sertraline
- Fluoxetine
- Escitalopram
- Venlafaxine
- Duloxetine
These may increase bleeding risk when combined with NSAIDs.
ACE Inhibitors and ARBs
Examples:
- Enalapril
- Lisinopril
- Ramipril
- Losartan
- Valsartan
NSAIDs may reduce antihypertensive effects and increase renal impairment risk.
Diuretics
Examples:
- Furosemide
- Hydrochlorothiazide
- Indapamide
NSAIDs may reduce diuretic effectiveness and increase renal toxicity.
The "Triple Whammy"
The combination of:
NSAID + ACE inhibitor/ARB + diuretic
can substantially increase the risk of acute kidney injury.
Particular caution and renal monitoring are warranted.
Lithium
NSAIDs may increase lithium concentrations and toxicity.
If concurrent therapy is necessary, lithium concentrations and clinical status may require monitoring.
Methotrexate
NSAIDs may reduce renal elimination of methotrexate and increase the risk of methotrexate toxicity, particularly with high-dose methotrexate or impaired renal function.
Clinically important monitoring is therefore required when the combination is used.
Cyclosporine and Tacrolimus
NSAIDs may increase nephrotoxicity associated with calcineurin inhibitors.
Digoxin
NSAIDs may potentially increase digoxin exposure and/or contribute to renal dysfunction.
Monitoring may be appropriate in susceptible patients.
CYP2C9 Interactions
Because CYP2C9 contributes substantially to meloxicam metabolism, strong CYP2C9 inhibitors or inducers may theoretically alter exposure.
However, the clinical importance depends on the interacting drug and patient characteristics.
17. Side Effects
Common/Relatively Common
Possible adverse effects include:
Gastrointestinal
- Dyspepsia
- Nausea
- Vomiting
- Abdominal pain
- Diarrhea
- Constipation
- Flatulence
- Heartburn
Neurological
- Headache
- Dizziness
- Somnolence
Cardiovascular/Renal
- Peripheral edema
- Increased blood pressure
- Fluid retention
Dermatological
- Rash
- Pruritus
The historical MOBITIL information specifically lists headache, drowsiness, tinnitus, dyspepsia, nausea, flatulence, diarrhea, constipation, peripheral edema, pruritus, and skin rash.
Serious Adverse Effects
Seek urgent medical evaluation for:
- Gastrointestinal bleeding
- Black/tarry stools
- Hematemesis
- Severe abdominal pain
- Chest pain
- Shortness of breath
- Sudden weakness
- Speech disturbance
- Severe allergic reaction
- Facial or throat swelling
- Severe bronchospasm
- Severe skin eruption
- Blistering
- Mucosal ulceration
- Marked reduction in urine output
- Unexplained severe edema
- Jaundice
18. Use in Special Populations
Pregnancy
Meloxicam should generally be avoided during pregnancy unless specifically indicated by a clinician after assessment of the benefit-risk balance.
A particularly important modern safety update concerns NSAID use from approximately 20 weeks of pregnancy onward.
FDA warns that NSAIDs at around 20 weeks or later may cause fetal renal dysfunction resulting in oligohydramnios and, in some cases, neonatal renal impairment. If an NSAID is considered necessary between 20 and 30 weeks, FDA recommends the lowest effective dose for the shortest possible duration and consideration of amniotic-fluid monitoring if treatment continues beyond 48 hours.
NSAIDs should generally be avoided from 30 weeks onward because of the additional risk of premature closure of the fetal ductus arteriosus.
Therefore, the old statement simply saying "pregnancy is contraindicated" is not sufficiently precise as a modern general NSAID safety statement. Pregnancy-specific restrictions are gestational-age dependent and should follow current regulatory guidance and the local approved product information.
Breastfeeding
Current evidence regarding meloxicam during lactation is limited.
The July 2025 LactMed review states that there is insufficient published information regarding meloxicam concentrations in breast milk or effects in breastfed infants and therefore suggests that other agents may be preferred, particularly when nursing a newborn or preterm infant.
Where an NSAID is required during breastfeeding, the choice should be individualized according to the clinical situation, infant age, maternal indication, dose, and treatment duration.
Pediatric Use
Pediatric approval depends on the specific formulation and regulatory jurisdiction.
Meloxicam has established use in some settings for juvenile idiopathic arthritis in children aged 2 years and older, but the pediatric indication and dosage should not automatically be transferred to every MOBITIL formulation.
The specific current Egyptian MOBITIL leaflet should be consulted before pediatric use.
Older Adults
Older adults have increased susceptibility to:
- Gastrointestinal bleeding
- Peptic ulceration
- Renal impairment
- Cardiovascular complications
- Fluid retention
The lowest effective dose for the shortest appropriate duration is preferred.
Renal Impairment
Use cautiously.
Particular concern exists in:
- Severe chronic kidney disease
- Dehydration
- Heart failure
- Elderly patients
- Patients receiving diuretics
- Patients receiving ACE inhibitors or ARBs
The historical MOBITIL information states that dialysis patients with severe renal failure should not exceed 7.5 mg/day.
This should be reconciled with the current approved product information before prescribing.
Hepatic Impairment
Patients with significant hepatic impairment require caution, and severe hepatic impairment is generally a reason to avoid meloxicam according to product labeling.
19. Storage Conditions
Storage conditions should be taken from the current package of the specific MOBITIL presentation, because storage requirements can differ between dosage forms.
The historical information supplied does not provide a definitive temperature for all presentations.
A current Egyptian pharmacy listing for MOBITIL suppositories reports storage at 2–8°C, whereas another Egyptian product listing gives a maximum temperature of 25°C, demonstrating that publicly available secondary sources are not sufficiently consistent to establish a universal storage instruction.
Therefore:
Store MOBITIL exactly according to the storage conditions printed on the current package/leaflet.
General precautions include:
- Keep out of reach of children.
- Protect from inappropriate heat and direct sunlight.
- Do not use after the expiration date.
- Do not use damaged or visibly altered ampoules, tablets, or suppositories.
20. Available MOBITIL Presentations in the Egyptian Market
Based on the current Egyptian-market information reviewed:
MOBITIL 7.5 mg Tablets
- Active ingredient: Meloxicam
- Strength: 7.5 mg/tablet
- Pack: 10 tablets
- Manufacturer: MUP
MOBITIL 15 mg Tablets
- Active ingredient: Meloxicam
- Strength: 15 mg/tablet
- Pack: 6 tablets
- Manufacturer: MUP
MOBITIL 15 mg/1.5 mL Ampoules
- Active ingredient: Meloxicam
- Strength: 15 mg/1.5 mL
- Pack: 3 ampoules
- Historical product information: deep IM administration
- Manufacturer: MUP
MOBITIL 15 mg Suppositories
- Active ingredient: Meloxicam
- Strength: 15 mg/suppository
- Pack: 6 suppositories
- Route: Rectal
- Manufacturer: MUP
MUP's product information available through an international pharmaceutical database identifies all three dosage-form categories—tablets, ampoules, and suppositories—and specifically lists the 7.5 mg tablet, 15 mg tablet, 15 mg suppository, and 15 mg ampoule presentations.
21. Important Corrections to the Older MOBITIL Commentary
The historical commentary supplied for this review contains useful product-specific information, but several statements require updating.
1. "Preferential COX-2 inhibitor"
This remains broadly correct, but meloxicam should not be described as a fully selective COX-2 inhibitor. It is a preferential COX-2 inhibitor within the therapeutic dose range.
2. Cardiovascular safety
The old leaflet does not adequately emphasize the modern NSAID cardiovascular warning.
Meloxicam can increase the risk of myocardial infarction and stroke, including potentially fatal events.
3. Gastrointestinal safety
The historical adverse-effect list is too limited.
GI bleeding, ulceration, and perforation are clinically important potential complications and can occur without warning.
4. Pregnancy
The old statement "pregnancy and breast-feeding" as a blanket contraindication is not sufficiently nuanced.
Current FDA guidance specifically highlights avoidance of NSAIDs beginning at approximately 20 weeks, with avoidance after 30 weeks, because of fetal renal and ductus arteriosus risks.
5. Breastfeeding
Modern evidence remains limited rather than establishing that meloxicam is categorically contraindicated during breastfeeding. LactMed's 2025 review recommends considering alternatives because of the absence of adequate milk/infant data.
6. Additional indications
The old MOBITIL document lists post-traumatic, postoperative, gynecological, dental, and vertebral pain indications. These should be regarded as historical product-information claims unless confirmed in the current Egyptian approved leaflet.
7. Injection route
The old MOBITIL information specifically describes deep intramuscular injection. This should not be generalized to all meloxicam injectable products, because other contemporary meloxicam injections may have different approved routes.
8. "Spectrum of activity"
Meloxicam has no antimicrobial spectrum because it is an NSAID rather than an antimicrobial drug.
22. Frequently Asked Questions (FAQ)
Is MOBITIL a steroid?
No. MOBITIL contains meloxicam, which is an NSAID. It is not a corticosteroid.
Is MOBITIL an antibiotic?
No. Meloxicam has no antibacterial or antimicrobial activity.
What is MOBITIL mainly used for?
It is primarily used for symptomatic relief of pain and inflammation associated with conditions such as osteoarthritis and rheumatoid arthritis, with additional approved uses depending on the formulation and jurisdiction.
Can MOBITIL be taken once daily?
Yes. Meloxicam is generally administered once daily because of its relatively long elimination half-life.
Is 15 mg/day the maximum usual dose?
For adults, 15 mg/day is generally the maximum recommended systemic daily dose. Higher doses do not normally provide an appropriate safety-benefit balance.
Can MOBITIL be combined with ibuprofen?
Routine combination with another systemic NSAID such as ibuprofen is not recommended, because it increases toxicity—particularly gastrointestinal and renal toxicity—without providing a useful therapeutic advantage.
Can MOBITIL cause stomach ulcers?
Yes. Like other systemic NSAIDs, meloxicam can cause gastric or duodenal ulceration, gastrointestinal bleeding, and perforation.
Is MOBITIL safer for the stomach than other NSAIDs?
Meloxicam's preferential COX-2 inhibition may provide some gastrointestinal tolerability advantages compared with certain nonselective NSAIDs, but it does not eliminate the risk of ulceration or GI bleeding.
Can MOBITIL cause kidney problems?
Yes. NSAIDs can reduce renal prostaglandin synthesis and precipitate acute kidney injury, particularly in susceptible patients.
Can MOBITIL increase blood pressure?
Yes. NSAIDs may cause sodium/fluid retention and may increase or worsen hypertension.
Can MOBITIL cause heart problems?
Yes. Systemic NSAIDs, including meloxicam, are associated with increased cardiovascular thrombotic risk, including myocardial infarction and stroke.
Can MOBITIL be used during pregnancy?
It should generally be avoided unless specifically indicated.
Particular caution is required from 20 weeks onward, and NSAIDs should generally be avoided from 30 weeks onward because of fetal renal and cardiovascular risks.
Can MOBITIL be used during breastfeeding?
There are insufficient human lactation data. The 2025 LactMed review suggests that alternative agents may be preferred, especially when breastfeeding a newborn or premature infant.
Is MOBITIL injection the same as MOBITIL tablets?
They contain the same active ingredient—meloxicam—but differ in dosage form, route, pharmacokinetic characteristics, and product-specific instructions. They should not be considered interchangeable on a milligram-for-milligram basis without considering the prescribed route and formulation.
Can the MOBITIL ampoule be given intravenously?
The historical MOBITIL information supplied for this Egyptian product specifies deep intramuscular administration.
The route should therefore be verified against the current MOBITIL ampoule leaflet before administration. Do not assume that an injectable meloxicam product can be administered by the same route as another meloxicam injection.
Can MOBITIL suppositories be swallowed?
No. Suppositories intended for rectal administration should be administered rectally.
Does MOBITIL contain meloxicam only?
The active pharmaceutical ingredient is meloxicam. Excipients may differ between tablets, ampoules, and suppositories and should be checked in the current package leaflet if excipient-specific information is required.
Does MOBITIL cause drowsiness?
Dizziness and somnolence can occur, although they are not necessarily experienced by every patient. Patients who experience these effects should avoid driving or operating machinery until they know how the medicine affects them.
Can MOBITIL be used for dental pain?
The historical MOBITIL information supplied with this review lists painful/inflammatory dental conditions. However, whether this remains a currently approved indication should be confirmed against the current Egyptian product information.
23. Overall Clinical Assessment
MOBITIL (meloxicam) is a well-established NSAID belonging to the oxicam class and remains a useful option for symptomatic treatment of inflammatory and degenerative musculoskeletal pain.
Its pharmacological advantages include:
- Once-daily administration
- Relatively long half-life
- Preferential COX-2 inhibition
- Established efficacy in osteoarthritis and rheumatoid arthritis
- Availability in multiple dosage forms in the Egyptian market
However, preferential COX-2 inhibition does not make meloxicam risk-free.
Clinically important risks include:
- Gastrointestinal ulceration and bleeding
- Acute kidney injury
- Fluid retention and edema
- Hypertension
- Cardiovascular thrombotic events
- Hepatic adverse effects
- Hypersensitivity reactions
- Severe cutaneous reactions
- Fetal renal toxicity and oligohydramnios during later pregnancy
- Premature closure of the fetal ductus arteriosus with later pregnancy exposure
The most appropriate general principle is therefore:
Use the lowest effective dose for the shortest duration necessary, after assessing gastrointestinal, cardiovascular, renal, hepatic, pregnancy, and drug-interaction risks.
Current meloxicam labeling continues to emphasize serious cardiovascular and gastrointestinal events, and contemporary pregnancy guidance has become more restrictive than many older product leaflets.
24. References
-
U.S. National Library of Medicine / DailyMed — Meloxicam Tablets, USP. Current U.S. prescribing information and boxed warnings regarding serious cardiovascular and gastrointestinal events.
-
U.S. Food and Drug Administration (FDA) — Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Drug Safety Communication. Guidance regarding avoidance of NSAIDs at 20 weeks or later in pregnancy and avoidance after 30 weeks.
-
MedlinePlus — Meloxicam. Clinical information regarding indications, administration, warnings, and precautions.
-
National Library of Medicine — LactMed: Meloxicam. Updated July 15, 2025; current evidence regarding breastfeeding and meloxicam exposure.
-
PubChem — Meloxicam. Pharmacokinetic information including protein binding, metabolism, CYP2C9/CYP3A4 involvement, elimination, and half-life.
-
Medical Union Pharmaceuticals / CPHI product information — MOBITIL. Product forms and strengths associated with MUP.
-
Egyptian-market pharmacy/product databases — MOBITIL. Current-market presentation information for tablets and suppositories.
-
Historical MOBITIL product information supplied for this commentary. Used for product-specific historical details, including the 15 mg/1.5 mL ampoule, historical indications, deep IM administration instructions, pharmacokinetic parameters, and manufacturer information. These historical details have been retained where useful but qualified where current evidence or regulatory recommendations have changed.
25. Final Disclaimer
We do not guarantee the accuracy, currency or completeness of information regarding medications or medical products, and official sources should be verified before making any decisions. By using this blog, you agree to assume personal responsibility for relying on the information provided.
This article is an educational drug-information commentary and is not a substitute for the current approved MOBITIL package leaflet, Egyptian regulatory information, prescribing information, or individualized medical advice. The information may change as regulatory authorities, manufacturers, and pharmacovigilance systems issue new safety information.